Annual Report

Overview

The report describes a focused 2025 strategy centered on three core assets, with abi-suva prioritized as the lead value driver. Final VB-C-02 Phase 2 data were published in January 2025 and are presented as confirming durable clinical benefit. The Group ended the year with cash and cash equivalents of 60,289 USD '000 and 59 year-end employees following restructuring. It also reports no significant environmental events or related non-compliance issues in 2025.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services